- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05574296
Hydrogen's Feasibility and Safety as a Therapy in ECPR (HydrogenFAST)
Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Each year, 500,000 patients in the US suffer a cardiac arrest and a growing number of them are resuscitated using ECPR. However, neurologic and renal injury remain important resulting comorbidities. The pathophysiology of these often-devastating injuries is ischemia (inadequacy of blood flow, at times compounded by hypoxemia) followed by an abrupt reperfusion (ECMO flow initiation). Among patients with congenital heart disease (CHD) receiving ECPR, 52% either die prior to discharge or suffer severe neurologic impairment. Diatomic hydrogen (H2) administration during and following ECPR may chemically reduce the toxic mediators that directly damage cellular structures and improve neurologically intact survival.
Preclinical data. Several groups have described that H2 inhalation decreases injury when administered following ischemic stroke, myocardial infarction, and cardiac arrest in rodents. Our group demonstrated that inhalation of 2.4% H2 for 24 hours following an experimental swine ischemia-reperfusion injury (as occurs in ECPR) improved neurologic scores, decreased seizures, diminished T2 white matter injury volume by 65%, and improved serum creatinine. Safety study in healthy participants. Under an investigator-initiated IND, we exposed 8 healthy adult participants to up to 72 hours of 2.4% H2 inhalation via high flow nasal cannula, finding no adverse effects on markers of hepatic, renal, cardiac or pulmonary function and no clinically significant symptoms reported. Having received a favorable pre-IND review from the FDA, we propose a two-center early phase study of H2 administration in patients with CHD receiving ECPR.
Study overview. We propose an early-phase randomized trial entitled the 'Hydrogen FAST Trial' (Hydrogen's Feasibility And Safety as a Therapeutic agent). The trial will have a 3-patient vanguard phase and 53 patients with CHD experiencing ECPR randomly assigned in a 3:2 (32/21) ratio to either usual care plus 2% H2 gas for 72 hours or to usual care. Patients will be recruited from two sites, Boston Children's Hospital and Texas Children's Hospital. We will primarily examine feasibility and safety (severe adverse events, independently adjudicated), as well as some indicators of efficacy.
Hypotheses. Feasibility endpoint: We hypothesize that H2 gas will be administered for >90% of the first 72 post-arrest hours in patients so-assigned and will be environmentally safe. Safety endpoint: We hypothesize that compared with patients receiving usual post-arrest care, patients receiving H2 will not exceed the treatment-related SAE rate of the usual care group by >12.5% in the 30 days following randomization.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: John N Kheir, MD
- Phone Number: 8576368890
- Email: john.kheir@childrens.harvard.edu
Study Contact Backup
- Name: Julia Mancebo, MD
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- John Kheir, MD
- Phone Number: 857-636-8890
- Email: john.kheir@childrens.harvard.edu
-
Principal Investigator:
- John Kheir, MD
-
Sub-Investigator:
- Victoria Habet, DO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Patients admitted to a cardiac intensive care unit at Boston Children's Hospital or Texas Children's Hospital with cardiac comorbidity, including congenital heart disease, myocarditis, cardiac arrhythmia, or rejection of a transplanted heart.
- Patients are anticipated to be between birth to 18 years of age, although occasionally a patient over the age of 18 may be enrolled.
- Patient experiencing a refractory cardiac arrest >5 minutes and receiving ongoing CPR in the ICU.
- The decision made by the clinical team to resuscitate from ongoing, refractory cardiac arrest using ECPR due to a lack of other available options.
EXCLUSION CRITERIA
Meeting any of the following criterion renders the patient ineligible for the trial:
- Enrollment in the opt-out program.
- Patients known to be pregnant.
- Patients who are prisoners.
- Prior ECPR episode during admission (whether or not they were enrolled in the trial).
- Enrollment does not occur within 2 hours of the decision to resuscitate using ECPR.
Note that ECMO cannulation without preceding CPR does not qualify as ECPR and such patients will not be included.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Usual care + H2 therapy
Hydrogen administered via mechanical ventilator and sweep gas into ECMO membrane for 72 hours
|
Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane.
Oxygen concentration titrated per clinical team.
Other Names:
Usual care post-ECPR event, including targeted temperature management.
Other Names:
|
Active Comparator: Usual care
The current standard of care.
|
Usual care post-ECPR event, including targeted temperature management.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of hydrogen administration
Time Frame: 72 hours
|
Percentage of the first 72 post-randomization hours (starting at the time of randomization) in which H2 gas was administered via all of the applicable pathways (e.g.
mechanical ventilator and ECMO membrane).
|
72 hours
|
Safety of hydrogen administration
Time Frame: 30 days
|
Incidence rate of SAEs of interest per day during the first 30 days post-randomization that have been classified as treatment-related or possibly treatment-related.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival to hospital discharge
Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 12 months
|
Survival to hospital discharge
|
From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 12 months
|
ICU length of stay
Time Frame: From date of randomization until the date of first ICU discharge or date of death from any cause, whichever came first, assessed up to 12 months
|
Duration of ICU stay until first transfer out of ICU
|
From date of randomization until the date of first ICU discharge or date of death from any cause, whichever came first, assessed up to 12 months
|
Hospital length of stay
Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 12 months
|
Duration of hospital stay until first hospital discharge
|
From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 12 months
|
Functional status score
Time Frame: Calculated on admission to the hospital, at 24 h before cardiac arrest, at hospital discharge, and at 6 months post-randomization
|
Functional status score computed based on a detailed review of neurology notes, primary team notes, nursing notes and physical exam documentation by two independent investigators.
|
Calculated on admission to the hospital, at 24 h before cardiac arrest, at hospital discharge, and at 6 months post-randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John N Kheir, MD, Associate Professor of Pediatrics, Harvard Medical School
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-P00043374
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extracorporeal Membrane Oxygenation
-
UMC UtrechtErasmus Medical Center; Catharina Ziekenhuis Eindhoven; St. Antonius Hospital; Leiden... and other collaboratorsRecruitingExtracorporeal Membrane Oxygenation | Extracorporeal Membrane Oxygenation ComplicationNetherlands
-
Transonic Systems Inc.National Heart, Lung, and Blood Institute (NHLBI)TerminatedCardiac Output | Venoarterial Extracorporeal Membrane Oxygenation | Venovenous Extracorporeal Membrane Oxygenation | Recirculation | Oxygenator Blood VolumeUnited States
-
Xiaobo Yang, MDRecruitingExtracorporeal Membrane OxygenationChina
-
Second Affiliated Hospital of Zhengzhou UniversityRecruitingExtracorporeal Membrane OxygenationChina
-
Policlinico HospitalThe Mediterranean Institute for Transplantation and Advanced Specialized...Completed
-
Rennes University HospitalCompletedExtraCorporeal Membrane OxygenationFrance
-
JinyanXingNot yet recruitingExtracorporeal Membrane OxygenationChina
-
Shanghai Zhongshan HospitalRecruitingExtracorporeal Membrane OxygenationChina
-
Daping Hospital and the Research Institute of Surgery...Beijing 302 Hospital; The First Hospital of Jilin University; Hunan Provincial... and other collaboratorsCompleted
-
National Taiwan University HospitalCompleted
Clinical Trials on Hydrogen
-
Navy General Hospital, BeijingRecruitingChronic Graft-versus-host DiseaseChina
-
HoHo BiotechRecruitingAutoimmune Diseases | Metabolic DiseaseTaiwan
-
HoHo BiotechTri-Service General HospitalRecruitingAutoimmune DiseasesTaiwan
-
Boston Children's HospitalCompleted
-
Universidad IberoamericanaCompleted
-
Stony Brook UniversityNatural Wellness Now Health ProductsRecruitingMyalgic Encephalomyelitis/Chronic Fatigue SyndromeUnited States
-
Stony Brook UniversityCompletedChronic Fatigue SyndromeUnited States
-
University of Novi Sad, Faculty of Sport and Physical...Completed
-
National Cancer Institute (NCI)CompletedNeurofibromatosis Type 1 | Cutaneous Neurofibroma | Optic Nerve GliomaUnited States
-
University of Novi Sad, Faculty of Sport and Physical...CompletedAging | Cognitive ImpairmentsSerbia